1578-96-7

Usage

Uses

Used in Laboratory Research:
(1-Methyl-1H-indazol-3-yl)methanol is used as a synthetic compound for various laboratory research applications. Its unique structure and properties make it a valuable compound for studying chemical reactions and interactions within controlled environments. (1-METHYL-1H-INDAZOL-3-YL)METHANOL's potential applications in research may include the development of new chemical processes, the synthesis of novel compounds, or as a reagent in various chemical analyses. Due to its synthetic nature, (1-methyl-1H-indazol-3-yl)methanol is not used in consumer products or industrial applications but remains an important tool for scientific exploration and discovery.

InChI:InChI=1/C9H10N2O/c1-11-9-5-3-2-4-7(9)8(6-12)10-11/h2-5,12H,6H2,1H3

Upstream product

• 109216-60-6 1-Methyl-1H-indazole-3-carboxylic acid methyl ester 
• 7732-18-5 water 
• 50890-83-0 1-methyl-1H-indazole-3-carboxylic acid 

Downstream Products

• 174180-57-5 1-methyl-3-bromomethyl-1H-indazole 
• 4002-83-9 1-methyl-1H-indazole-3-carbaldehyde 
• 1578-97-8 3-(chloromethyl)-1-methyl-1H-indazole 
• 1228935-24-7 {4-[(1-methyl-1H-indazol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}acetic acid. 
• 1228935-23-6 tert-butyl {4-[(1-methyl-1H-indazol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}acetate 
• 1228934-72-2 6-{2-[2-(2-methoxyethyl)piperidin-1-yl]-2-oxoethyl}-4-[(1-methyl-1H-indazol-3-yl)methyl]-1-phenyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5(6H)-one 
• 1228934-65-3 6-{2-[(2R)-2-(3,5-dimethylbenzyl)piperidin-1-yl]-2-oxoethyl}-4-((1-methyl-1H-indazol-3-yl)methyl)-1-phenyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5(6H)-one 
• 174181-81-8 N-Isopropyl-N-(4-methoxy-phenyl)-2-[3-(1-methyl-1H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]acetamide 

Relevant academic research and scientific papers

DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION

Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS

The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phospho

THERAPEUTIC AGENTS I

Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives

Benzo?b!?1,4!diazepine compounds of formula (I), where R1 is selected from C1 C6 alkyl, C3 -C6 cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3 -C6 alkyl, C3 C6 cycloalkyl, C3 -C6 alkenyl, benzyl, phenylC1 -C3 alkyl of substituted phenyl; or NR1 R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6 alkyl C1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6 alkyl; R4 is C1-6 alkyl or C1-6 alkenyl; R7 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6 R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).